S. Gray

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

K. Ataga, E. Vichinsky, I. Agodoa, 2020 .

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease

B. Biemond, J. Knight-Madden, C. Minniti, 2021, American journal of hematology.

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.

K. Ataga, E. Vichinsky, I. Agodoa, 2021, The Lancet. Haematology.

5572697 TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE

P. Yue, A. Inati, C. Minniti, 2023, HemaSphere.

Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.

J. Hanft, P. Kwon, A. Barbul, 2008, Journal of wound care.

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

K. Ataga, E. Vichinsky, V. Gordeuk, 2020 .